Abbott Laboratories news

   Watch this stock
Showing stories 1 - 10 of about 112   

Articles published

ABT 50.75 -0.02 (-0.04%)
price chart
Abbott Laboratories to buy Roseville-based Tendyne for $250 million
Illinois-based Abbott expects to close its acquisition of Tendyne by the end of September, pending approval from antitrust regulators.
Abbott Laboratories to buy heart-valve maker Tendyne $225M  ModernHealthcare.com
Abbott Labs makes 2 heart valve replacement deals  Chicago Tribune
Insider Selling: Abbott Laboratories (ABT), Pandora Media Inc. (P) And Google ...
Bidness Etc reports the latest insider selling at Abbott Laboratories (NYSE:ABT), Pandora Media Inc (NYSE:P) and Google Inc (NASDAQ:GOOGL).
Abbott Laboratories Given "Buy" Rating at BTIG Research (ABT)  Dakota Financial News
What after Brian Blaser's Insider Sale of Abbott Laboratories (NYSE:ABT ...  OctaFinance.com
Abbott Labs Profit Beats Expectations
Medical devices sales dipped 6.1%. Abbott affirmed its 2015 guidance, saying it expects earnings on a per-share to land between $2.10 and $2.20.
ABBOTT LABORATORIES (ABT) Earnings Report: Q2 2015 Conference Call Transcript  TheStreet.com
Abbott Laboratories reports strong sales growth  Chicago Tribune
Profit from Emerging Market Health Care Growth With Abbott Laboratories
The company saw adjusted earnings-per-share grow 6.1% to $0.52 per share from $0.49 per share in the same quarter a year ago. Abbott Laboratories left its adjusted earnings-per-share guidance for full fiscal 2015 unchanged at $2.10 to $2.20 per share.
Abbott Laboratories (ABT) Beats on Q2 Earnings, Keeps View
Abbott Labs operates through four segments, namely, Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition.
Abbott Laboratories, Boston Scientific & Medtronic Drug-Eluting Stents ...
Abbott Laboratories has been the leading competitor in the drug-eluting stent (DES) market with over 30% market share. Their actual selling price for DES has been quite low due to competition with Boston Scientific.
Abbott Labs beats Street 2Q forecasts
ABBOTT PARK - Abbott Laboratories (ABT) on Wednesday reported first-quarter net income of $2.29 billion. The Abbott Park, Illinois-based company said it had net income of $1.51 per share.
Abbott beats Street 2Q forecasts  Lexington Herald Leader
Abbott Laboratories Given Average Rating of "Buy" by Brokerages (NYSE:ABT)
Abbott Laboratories logo Shares of Abbott Laboratories (NYSE:ABT) have been given a consensus rating of “Buy” by the seventeen brokerages that are presently covering the stock, Analyst Ratings Network.
Analyst Rating Update on Abbott Laboratories  Money Flow Index
Earnings Surprise in Focus - Abbott Laboratories (NYSE:ABT)  Investor Newswire
Abbott Laboratories is Expected to Report $0.54 for Q2
Wall Street analysts expect Abbott Laboratories (NYSE:ABT) to report earnings per share of $0.54 for the current fiscal quarter.
Large Inflow of Money Witnessed in Abbott Laboratories  American Trade Journal
Will Abbott Laboratories (ABT) Miss Earnings This Season?
Our proven model does not conclusively shows that Abbott Labs is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an ...